IN THE CLAIMS

Please amend the claims as follows:

- 1. (Currently Amended) A coupling syringe system comprising:
- a first syringe including a first syringe barrel having a first syringe open proximal end and a first syringe distal end, the first syringe further including a first syringe tip with an integral male end portion and a locking ring, wherein the locking ring is spaced from an outer surface of the male end portion;
- a first syringe plunger slidably disposed within the first syringe barrel and configured to move to a position at the first syringe distal end, the first syringe plunger in fluid-tight engagement with an inner surface of the first syringe barrel;
- a second syringe including a second syringe barrel having a second syringe open proximal end and a second syringe distal end, the second syringe further including a second syringe tip with an integral female end portion and one or more exteriorly protruding members adapted to detachably fit the locking ring, wherein the female end portion has an opening defined by an opening wall, which supports the one or more exteriorly protruding members; and
- a second syringe plunger slidably disposed within the second syringe barrel and configured to move to a position at the second syringe distal end, the second syringe plunger in fluid-tight engagement with an inner surface of the second syringe barrel,

wherein the first syringe and the second syringe are each sized to contain a single dose, and

wherein, when the first and second syringes are coupled, the male end portion is received by the opening of the female end portion, and the opening wall and the one or more exteriorly protruding members are received by the spacing between the locking ring and the outer surface of the male end portion, thereby allowing for a single, fluid tight attachment site configured for back and forth transfer of one or more a first and a second composition[[s]] between the first syringe and second syringes, wherein a mixing volume of the first and second compositions is substantially fully transitioned between the first and second syringes in corresponding first and second mixing configurations:

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.116 - EXPEDITED PROCEDURE

Serial Number:10/634,656

Filing Date: August 5, 2003

Title: COUPLING SYRINGE SYSTEM AND METHODS FOR OBTAINING A MIXED COMPOSITION

Dkt: 1195.323US1

Page 3

in the first mixing configuration, the mixing volume is substantially fully retained

within the first syringe, and

in the second mixing configuration, the mixing volume is substantially fully

retained within the second syringe.

2. (Canceled).

3. (Previously Presented) The coupling syringe system of claim 1, wherein the locking ring

is configured to detachably connect to a discharge assembly.

4. (Previously Presented) The coupling syringe system of claim 3, wherein the discharge

assembly comprises a needle cannula and a hub joined to a proximal end of the cannula, and

wherein the male end portion at least partially fits into, and frictionally engages, the hub when

the discharge assembly and the locking ring are detachably connected.

5. (Previously Presented) The coupling syringe system of claim 1, wherein the integral

female end portion of the second syringe is detachably connected to the integral male end portion

of the first syringe via engagement of the one or more exteriorly protruding members and one or

more threads on an inward-oriented surface of the locking ring, which extend toward a syringe

axis.

6. (Previously Presented) The coupling syringe system of claim 1, wherein the integral

female end portion of the second syringe is detached from the integral male end portion of the

first syringe.

7. (Original) The coupling syringe system as recited in claim 1, further comprising an

outwardly projecting flange near the first syringe proximal end.

8. (Original) The coupling syringe system as recited in claim 1, further comprising an

outwardly projecting flange near the second syringe proximal end.

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.116 - EXPEDITED PROCEDURE

Serial Number:10/634,656

Filing Date: August 5, 2003

Title: COUPLING SYRINGE SYSTEM AND METHODS FOR OBTAINING A MIXED COMPOSITION

9. (Previously Presented) The coupling syringe system as recited in claim 1, wherein the

locking ring is rotatably coupled relative to the integral male end portion of the first syringe.

10. (Previously Presented) The coupling syringe system as recited in claim 1, wherein the

locking ring surrounds the male end portion and is threadingly coupled with the one or more

exteriorly protruding members, and wherein the one or more exteriorly protruding members are

disposed on an outward-oriented surface of the opening wall, extending away from a syringe

axis, of the female end portion.

11. (Previously Presented) The coupling syringe system as recited in claim 1, wherein the

integral male end portion of the first syringe is disposed within the integral female end portion of

the second syringe.

12. (Previously Presented) The coupling syringe system as recited in claim 1, wherein the

locking ring is rotatably coupled relative to the integral male end portion of the first syringe and

the locking ring is threadingly coupled with the one or more exteriorly protruding members of

the second syringe.

13. (Currently Amended) The coupling syringe system as recited in claim 1, wherein at least

one of the first and second syringes contains therein a the first composition includes including a

drug delivery system.

14. (Currently Amended) The coupling syringe system as recited in claim 13, wherein the

other syringe contains therein a second composition includes including a drug.

15. (Previously Presented) The coupling syringe system as recited in claim 14, wherein the

drug includes lyophilized leuprolide acetate.

Page 4 Dkt: 1195.323US1

Page 5

Title: COUPLING SYRINGE SYSTEM AND METHODS FOR OBTAINING A MIXED COMPOSITION

16. (Previously Presented) The coupling syringe system as recited in claim 13, wherein the drug delivery system includes Poly (D,L-lactide-co-glycolide) dissolved in a biocompatible solvent N-methyl 2-pyrrolidone.

- 17. (Previously Presented) The coupling syringe system as recited in claim 1, wherein the first syringe is directly coupled to the second syringe such that no independent coupling means is present therebetween.
- 18. (Previously Presented) The coupling syringe system as recited in claim 1, wherein the first syringe is configured for administration to a patient and wherein the first syringe is approximately the same size as the second syringe.
- 19. (Canceled).
- 20. (Previously Presented) The coupling syringe system as recited in claim 1, wherein the first syringe including the first syringe tip with the integral male end portion is defined by a unitary body; and

wherein the second syringe including the second syringe tip with the integral female end portion is defined by a unitary body.

- 21. (Currently Amended) A coupling syringe system for forming a mixed medical composition, the system consisting of:
- a first single dose syringe including a first syringe barrel having a first syringe open proximal end and a first syringe distal end, the first syringe further including an outwardly projecting flange and a first syringe tip with an integral male end portion and a locking ring, wherein the locking ring is spaced from an outer surface of the male end portion, the first syringe barrel having a first syringe inner surface;
- a first syringe plunger slidably disposed within the first syringe barrel and configured to move to a position at the first syringe distal end, the first syringe plunger in fluid-tight engagement with the first syringe inner surface;

a second single dose syringe including a second syringe barrel having a second syringe open proximal end and a second syringe distal end, the second syringe further including an outwardly projecting flange and a second syringe tip with an integral female end portion, wherein the female end portion comprises one or more exteriorly protruding members adapted to detachably fit the locking ring and an opening defined by an opening wall, the second syringe barrel having a second syringe inner surface;

a second syringe plunger slidably disposed within the second syringe barrel and configured to move to a position at the second syringe distal end, the second syringe plunger in fluid-tight engagement with the second syringe inner surface;

a drug delivery system disposed in one of the first and second syringes; and a drug disposed in the other of the first and second syringes,

wherein, when the first and second syringes are coupled, the male end portion is received by the opening of the female end portion, and the opening wall and the one or more exteriorly protruding members are received by the spacing between the locking ring and the outer surface of the male end portion, thereby allowing for a single, fluid tight attachment site configured for back and forth transfer of the drug delivery system and the drug between the first syringe and second syringe, wherein a mixing volume of the drug delivery system and the drug is substantially fully transitioned between the first and second syringes in corresponding first and second mixing configurations:

in the first mixing configuration, the mixing volume is substantially fully retained within the first syringe, and

in the second mixing configuration, the mixing volume is substantially fully retained within the second syringe.

22. (Previously Presented) The coupling syringe system as recited in claim 21, wherein the locking ring couples the first syringe to the second syringe and forms a fluid tight engagement configured for back and forth transfer of the drug delivery system and the drug between the syringes.

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.116 - EXPEDITED PROCEDURE

Serial Number:10/634,656

Filing Date: August 5, 2003

Title: COUPLING SYRINGE SYSTEM AND METHODS FOR OBTAINING A MIXED COMPOSITION

23. (Previously Presented) The coupling syringe system as recited in claim 21, wherein the drug includes lyophilized leuprolide acetate.

Page 7

Dkt: 1195.323US1

- 24. (Previously Presented) The coupling syringe system as recited in claim 21, wherein the drug delivery system includes Poly (D,L-lactide-co-glycolide) dissolved in a biocompatible solvent N-methyl 2-pyrrolidone.
- 25. (Previously Presented) The coupling syringe system as recited in claim 21, wherein, when the first and second syringes are coupled, movement of the first syringe plunger toward the second syringe effectuates delivery of one or both of the drug delivery system or the drug through the male end portion and directly into the second syringe barrel.
- 26. (Previously Presented) The coupling syringe system as recited in claim 21, wherein the receipt of the male end portion by the female end portion forms a mixing region, the mixing region configured to be at least partially detachable from the first dose syringe and at least partially detachable from the second dose syringe.